MMQ

ABO - Óskare Capital: Partnership Announcement

Retrieved on: 
Wednesday, January 26, 2022

Alpha Blue Ocean (ABO) and skare Capital are announcing today the formation of a strategic partnership to collaborate on investment opportunities associated with cannabis plant-based medicines as well as synthetic molecules that target the mammalian Endocannabinoid system (ECS).

Key Points: 
  • Alpha Blue Ocean (ABO) and skare Capital are announcing today the formation of a strategic partnership to collaborate on investment opportunities associated with cannabis plant-based medicines as well as synthetic molecules that target the mammalian Endocannabinoid system (ECS).
  • Furthermore, because of favorable valuations there are readily available opportunities for ABO and skare to invest in and scale.
  • skare Capitals Chairman, Bruce Linton notes: skare Capital is delighted to be joining forces with ABO.
  • skare surrounded themselves with a stellar team whose experience spans all sectors of this new multibillion dollar industry.

FDA Clears MindMed IND for MM-120 in Treatment of Generalized Anxiety Disorder

Retrieved on: 
Tuesday, January 25, 2022

The previously announced clinical hold on the IND was lifted following MindMed's rapid responses for additional information related tothe participant monitoring protocol in the upcoming study.

Key Points: 
  • The previously announced clinical hold on the IND was lifted following MindMed's rapid responses for additional information related tothe participant monitoring protocol in the upcoming study.
  • "FDA clearance of our Phase 2b clinical trial represents a major milestone, for MindMed and for the industry as a whole," said Robert Barrow, Chief Executive Officer and Director of MindMed.
  • GAD is a chronic, often debilitating mental health disorder that affects approximately 6% of U.S. adults in their lifetimes.
  • LSD has been investigated for its applications in the treatment of anxiety associated with terminal cancer, alcoholism, opioid use disorder, and depression, among other conditions.

Stephen Hurst Resigns from MindMed Board of Directors

Retrieved on: 
Friday, January 7, 2022

NEW YORK, Jan. 7, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-derived therapies, announces the resignation of Stephen Hurst from his role as a Director of the Company's Board of Directors.

Key Points: 
  • NEW YORK, Jan. 7, 2022 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-derived therapies, announces the resignation of Stephen Hurst from his role as a Director of the Company's Board of Directors.
  • "On behalf of MindMed, the Board of Directors, and the Executive team, I thank Steve for his significant contributions and strategic guidance in bringing the Company to this stage of development," said Robert Barrow, Chief Executive Officer and Director of MindMed.
  • "The co-founders and early leadership of MindMed have been instrumental in establishing the Company and its strong foundation.
  • The MindMed executive team brings extensive biopharmaceutical experience to MindMed's approach to developing the next generation of psychedelic-inspired medicines and therapies.

MindMed Announces Transitions to Management Team

Retrieved on: 
Wednesday, December 29, 2021

NEW YORK, Dec. 29, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announced that its Chief Technology Officer, Bradford Cross, has transitioned from his role.

Key Points: 
  • "We remain dedicated to advancing our pipeline and ongoing digital therapeutics platform forward under the leadership of MindMed Chief Medical Officer, Dr. Daniel Karlin.
  • MindMed is a clinical-stage biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness.
  • The MindMed executive team brings extensive biopharmaceutical experience to MindMed's approach to developing the next generation of psychedelic-inspired medicines and therapies.
  • MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.

MindMed to Present at H.C. Wainwright 2nd Annual Psychedelics Conference

Retrieved on: 
Wednesday, December 1, 2021

A webcast of the company presentation will be available on-demand through the H.C. Wainwright conference portal beginning Monday, December 6, 2021 at 7:00 a.m.

Key Points: 
  • A webcast of the company presentation will be available on-demand through the H.C. Wainwright conference portal beginning Monday, December 6, 2021 at 7:00 a.m.
  • MindMed is a clinical-stage psychedelic medicine biotech company that seeks to discover, develop and deploy psychedelic-inspired medicines and therapies to address addiction and mental illness.
  • The MindMed executive team brings extensive biopharmaceutical experience to MindMed's approach to developing the next generation of psychedelic-inspired medicines and therapies.
  • MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.

MindMed Launches Study of Low-Dose LSD Effects on Sleep and Cognitive Measures

Retrieved on: 
Tuesday, November 16, 2021

Researchers will use digital measurement devices and software to measure the effects of microdoses of LSD on neuroplasticity markers such as BDNF plasma levels, as well as on various sleep measures, mood, cognitive performance, regulation of emotions, quality of life, and immune system response.

Key Points: 
  • Researchers will use digital measurement devices and software to measure the effects of microdoses of LSD on neuroplasticity markers such as BDNF plasma levels, as well as on various sleep measures, mood, cognitive performance, regulation of emotions, quality of life, and immune system response.
  • The study will be conducted by Dr. Kim Kuypers of Maastricht University, a leading global authority on the use of low dose psychedelics.
  • The MindMed executive team brings extensive biopharmaceutical experience to MindMed's approach to developing the next generation of psychedelic-inspired medicines and therapies.
  • Except as required by law, the Company does not intend and does not assume any obligation to update this forward-looking information.

MindMed to Present at the Jefferies London Healthcare Conference

Retrieved on: 
Friday, November 12, 2021

NEW YORK, Nov. 12, 2021 /PRNewswire/ --Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that its CEO, Robert Barrow, will be speaking at Jefferies 2021 London Healthcare Conference, taking place on November 16-19.

Key Points: 
  • NEW YORK, Nov. 12, 2021 /PRNewswire/ --Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that its CEO, Robert Barrow, will be speaking at Jefferies 2021 London Healthcare Conference, taking place on November 16-19.
  • MindMed will maintain an archived replay of the webcast on its website for 30 days after the conference.
  • The MindMed executive team brings extensive biopharmaceutical experience to MindMed's approach to developing the next generation of psychedelic-inspired medicines and therapies.
  • MindMed trades on the NASDAQ under the symbol MNMD and on the Canadian NEO Exchange under the symbol MMED.

MindMed to Present at Web Summit on Future of Mental Health

Retrieved on: 
Monday, November 1, 2021

Barrow will be interviewed at 11:45am WET on November 3 on the topic, " Therapy 2.0 - The next step in mental health ".

Key Points: 
  • Barrow will be interviewed at 11:45am WET on November 3 on the topic, " Therapy 2.0 - The next step in mental health ".
  • The session will touch on MDMA dosing, psychedelic precision medicine, LSD neutralising and similar themes around the future for specialised mental health treatment.
  • Web Summit is an annual technology conference that brings together the people and companies redefining the global tech industry.
  • Politico calls it the "world's premier tech conference", while The Atlantic says that Web Summit is "where the future goes to be born".

MindMed Announces Appointment of Andreas Krebs and Carol Vallone as Directors and Transition of Bruce Linton

Retrieved on: 
Thursday, September 30, 2021

NEW YORK, Sept. 30, 2021 /PRNewswire/ -- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ) ("MindMed" or the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce that its board of directors has appointed Mr. Andreas Krebs and Ms. Carol Vallone as directors of the Company, effective immediately.

Key Points: 
  • Ms. Vallone is a well-known business leader, former CEO, and corporate board director, with a strong track record in launching, scaling and selling global companies.
  • Effective September 29, 2021, Mr. Bruce Linton stepped down from the Company's board of directors in order to make room for the appointment of Ms. Vallone and Mr. Krebs.
  • MindMed Chair Perry Dellelce said,"We are extremely happy to welcome Carol and Andreas to the Board.
  • The appointment of Mr. Krebs and Ms. Vallone is subject to regulatory approval.

MindMed Appoints University of North Carolina Psychiatrist and Pharmacologist Dr. Bryan Roth to Scientific Advisory Board

Retrieved on: 
Wednesday, September 29, 2021

He is the Michael Hooker Distinguished Professor in the Department of Pharmacology at the University of North Carolina's (UNC) School of Medicine.

Key Points: 
  • He is the Michael Hooker Distinguished Professor in the Department of Pharmacology at the University of North Carolina's (UNC) School of Medicine.
  • MindMed CEO Robert Barrow said, "We are thrilled to welcome Dr. Roth to our Scientific Advisory Board.
  • MindMed's Scientific Advisory Board is composed of a diverse group of members with expertise in psychiatry, neuroscience, and clinical development.
  • Members represent institutions such as Johns Hopkins University, New York University Langone Health, Duke University, the National Institutes of Health, Stanford University, and Massachusetts General Hospital.